On April 16, 2026, President Donald Trump announced his nomination of Dr. Erica Schwartz, a former Coast Guard officer and deputy surgeon general, to lead the Centers for Disease Control and Prevention (CDC). The move comes after months of leadership turmoil at the embattled agency and marks a pivotal moment in the Biden administration’s ongoing struggle to steady the nation’s top public health institution.
Schwartz’s nomination, revealed in a lengthy post on Trump’s Truth Social platform, capped off a months-long search for a permanent CDC director. Trump praised Schwartz as “incredibly talented” and a “STAR,” highlighting her academic credentials from Brown University and her distinguished service in the United States Public Health Service Commissioned Corps, where she rose to the rank of rear admiral in the Coast Guard. According to CNN, Schwartz was instrumental in developing Coast Guard policy on pandemic influenza and other viral disease outbreaks, and she played a major role in the U.S. response to the Covid-19 pandemic during Trump’s first term.
Schwartz’s appointment is one of several high-profile personnel moves at the CDC. Trump also named Sean Slovenski, a former Walmart executive, as deputy director and chief operating officer; Dr. Jennifer Shuford, former Texas health commissioner, as deputy director and chief medical officer; and Dr. Sara Brenner, a former Food and Drug Administration official, as senior counselor for public health to Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. As Reuters reported, these appointments represent a shift toward more traditional candidates for top health agency roles, a move seen as an attempt to restore stability and credibility to the CDC after a period of intense controversy.
The CDC has been in a state of upheaval since Trump’s return to office more than a year ago. The agency has cycled through a succession of mostly temporary leaders, with morale plummeting and staff turnover rising. The roots of this instability trace back to last summer, when Susan Monarez, the only Senate-confirmed CDC director during Trump’s second term, was fired less than a month into her tenure. Monarez’s dismissal reportedly stemmed from her refusal to approve vaccine recommendations without a thorough review of the scientific evidence—a stance she defended in congressional testimony last September. “I could not pre-approve recommendations without reviewing the evidence, and I had no basis to fire scientific experts,” Monarez told lawmakers. “Even under pressure, I could not replace evidence with ideology or compromise my integrity.”
Following Monarez’s firing, the CDC saw a wave of resignations among key scientific leaders, who lamented the loss of a director willing to guard against political interference in the agency’s research and recommendations. The role of acting director passed from one Health and Human Services official to another, with National Institutes of Health Director Jay Bhattacharya overseeing the CDC in recent weeks. However, Bhattacharya’s tenure as acting director expired last month under the federal Vacancies Act, which limits acting service to 210 days, leaving the agency in limbo until Schwartz’s nomination.
Schwartz’s nomination comes at a time when the CDC is grappling with not only internal turmoil but also external challenges, including the resurgence of measles and legally contested changes to routine vaccine recommendations. Under the watch of Health Secretary Robert F. Kennedy Jr., the agency has pursued a controversial overhaul of the childhood vaccine schedule, a move that has faced significant pushback from both the scientific community and the public. A Massachusetts judge recently blocked key parts of Kennedy’s effort, including a proposal to reduce the number of recommended childhood shots from 17 to 11 and an overhaul of the CDC’s advisory committee on inoculations, as reported by Reuters and Politico.
Public trust in the CDC and other federal health agencies has plummeted during Kennedy’s tenure, with polling from the health policy research group KFF showing declines across the political spectrum. The White House, according to sources familiar with internal discussions, has sought to shift the agency’s focus toward more popular issues such as lowering drug prices and food safety, in hopes of shoring up support ahead of a challenging midterm election season for Republicans.
Despite her extensive experience—24 years in the US Public Health Service Commissioned Corps, oversight of 41 clinics and 150 sick bays in the Coast Guard, and a major role in pandemic preparedness—Schwartz’s nomination has not been without controversy. While she has been praised by former public health officials for her leadership during the COVID response, she has also faced criticism from some quarters. Aaron Siri, a lawyer and ally of Kennedy known for his opposition to vaccines and pharmaceutical companies, lambasted Schwartz’s history of enforcing vaccine mandates in the military. “Her long track record of directly issuing rights-crushing civilian and military vaccine mandates, including mandating injection of smallpox, anthrax, and flu vaccines into U.S. Forces, and disciplining those that refused, reflects she lacks the basic ethics and morals to lead the CDC,” Siri wrote in a social media post. “This agency does not need another cheerleader for industry.”
On the other hand, Demetre Daskalakis, former CDC director of the National Center for Immunization and Respiratory Diseases who resigned after Monarez’s firing, commended Schwartz’s “good leadership” and “proven track record... notably with pandemic preparedness.” Many public health experts see her as a stabilizing force at a time when the CDC desperately needs to rebuild credibility and morale.
Schwartz’s views on vaccines and other key public health policies remain largely unpublicized, raising questions about how she will navigate the tense landscape shaped by Kennedy’s controversial agenda. Her confirmation hearing before the Senate Health, Education, Labor and Pensions Committee has not yet been scheduled, and both supporters and critics will be watching closely for any indication of how she intends to balance scientific integrity with political pressures.
The stakes are high. The CDC director traditionally has the final say on U.S. vaccine policy, and with recent measles outbreaks and ongoing debates over childhood immunizations, the agency’s leadership will play a crucial role in shaping the nation’s public health response. As the Associated Press noted, the White House’s push for more traditional candidates and the Senate’s skepticism toward Kennedy’s direction for the department reflect broader concerns about political meddling in science and the future of evidence-based policy at the CDC.
In a social media post, Kennedy congratulated Schwartz and the other new appointees, expressing hope for a new era at the CDC. “I look forward to working together to restore trust, accountability, and scientific integrity at the CDC,” Kennedy wrote. Whether Schwartz can deliver on that promise remains to be seen, but her nomination marks a decisive step in the ongoing struggle to restore stability and confidence at America’s leading public health agency.